CLINICAL SCIENCE

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial


RITAZAREM co-investigators

Handling editor Josef S Smolen

Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/ard-2022-223559).

For numbered affiliations see end of article.

Correspondence to
Dr Rona M Smith, Medicine, University of Cambridge, Cambridge CB2 1TN, UK; rms50@cam.ac.uk

Received 22 January 2023
Accepted 6 March 2023

ABSTRACT

Objective Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of relapse. Relapses are associated with increased exposure to immunosuppressive medications, the accrual of damage and increased morbidity and mortality. The RITAZAREM trial compared the efficacy of repeat-dose rituximab to daily oral azathioprine for prevention of relapse in patients with relapsing AAV in whom remission was reinduced with rituximab.

Methods RITAZAREM was an international randomised controlled, open-label, superiority trial that recruited 188 patients at the time of an AAV relapse from 29 centres in seven countries between April 2013 and November 2016. All patients received rituximab and glucocorticoids to reinduce remission. Patients achieving remission by 4 months were randomised to receive rituximab intravenously (1000 mg every 4 months, month 20) (85 patients) or azathioprine (2 mg/kg/day, tapered after month 24) (85 patients) and followed for a minimum of 36 months. The primary outcome was time to disease relapse (either major or minor relapse).

Results Rituximab was superior to azathioprine in preventing relapse: HR 0.41, 95% CI 0.27 to 0.61, p<0.001. 19/85 (22%) patients in the rituximab group and 31/85 (36%) in the azathioprine group experienced at least one serious adverse event during the treatment period. There were no differences in rates of hypogammaglobulinaemia or infection between groups.

Conclusions Following induction of remission with rituximab, fixed-interval, repeat-dose rituximab was superior to azathioprine for preventing disease relapse in patients with AAV with a prior history of relapse.

Trial registration number NCT01697267; ClinicalTrials.gov identifier

WHAT IS ALREADY KNOWN ON THIS TOPIC?

⇒ Rituximab is superior to azathioprine for the prevention of major relapse following cyclophosphamide induction therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV).

WHAT THIS STUDY ADDS?

⇒ These data confirm the place of rituximab as the standard of care for maintenance therapy. But, despite a higher dose rituximab regimen, relapses still occurred during treatment, and there was an increased risk of relapse after stopping rituximab.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY?

⇒ The ongoing relapse risk together with associated safety concerns of extended rituximab therapy illustrate the need for newer therapeutic agents in AAV.

BACKGROUND

Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the major subgroups of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).\(^1\) Untreated, AAV has a mortality of 93% within 2 years, primarily due to renal and respiratory failure.\(^2\) The introduction of glucocorticoids and cyclophosphamide improved survival, inducing remission at 1 year in 80% of patients. B-lymphocytes contribute to the pathogenesis of AAV and rituximab is an effective therapy for induction of remission and is superior...
to cyclophosphamide for the treatment of relapsing disease. However, over 50% of patients relapse within 5 years of diagnosis, including after induction of remission with rituximab, especially in patients with a history of relapse. Relapses reflect further episodes of inflammation and contribute to irreversible tissue damage, end-stage kidney failure, treatment-related toxicity, chronic morbidity, increased mortality and high health-related costs. More-effective strategies to prevent relapse in AAV are needed.

Fixed-interval, repeat dose rituximab was superior to azathioprine as a maintenance strategy in a largely newly diagnosed AAV after induction with cyclophosphamide and glucocorticoid in the MAINRITSAN 1 trial. However, prolonged use of rituximab in AAV has been associated with an increased risk of infection and the development of hypogammaglobulinaemia. The optimal strategy to maintain remission following induction of remission with rituximab, especially for treatment of relapse, remains unclear.

RITAZAREM was an international, randomised, controlled trial designed to assess whether fixed-interval rituximab was superior to azathioprine for the maintenance of remission following induction of remission with rituximab and glucocorticoids in patients with relapsing AAV. Furthermore, it was hypothesised that increased doses of rituximab would reduce the risk of relapse beyond the maintenance treatment period.

METHODS

Study design
The RITAZAREM trial had three phases. The protocol design and results of the induction phase have been reported.

1. Induction phase (enrolment through month 4): induction therapy comprised of rituximab (four doses of 375 mg/m²/week) and oral prednisone/prednisolone commencing at either 1.0 mg/kg/day (high dose) or 0.5 mg/kg/day (low dose), both reducing to 10 mg/day or less, selected at physician discretion. Intravenous methylprednisolone up to a cumulative dose of 3000 mg was permitted in the 2 weeks before or 1 week after enrolment.

2. Maintenance phase: (4–24 months from enrolment). Patients who had achieved remission, defined as a Birmingham Vasculitis Activity Score for Wegener’s granulomatosis (BVAS/WG) ≤1 and prednisone/prednisolone dose ≤10 mg/day, were randomised to receive rituximab or azathioprine.

3. Follow-up phase: this off-treatment phase commenced after completion of the maintenance phase at month 24 and lasted for a further 12–24 months (36–48 months from enrolment). This paper reports the results of the maintenance and follow-up phases of the trial.

Patients
Patients were aged over 15 years and had a diagnosis of GPA or MP A according to the Chapel Hill Consensus Conference 2012 definitions, and a current or prior positive test for proteinase 3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA. All patients had disease relapse defined by one major or three minor item of disease activity on the BVAS/WG after achieving remission following therapy with a combination of glucocorticoids and an immunosuppressive agent. Patients with other multisystem autoimmune diseases were excluded.

Patients were recruited from 29 centres in seven countries between April 2013 and November 2016. The last patient visit was in November 2019.

Randomisation and masking
RITAZAREM was an open-label, unblinded study. Patients who achieved disease remission by month 4 were randomised into the maintenance phase using a web-based system in a 1:1 ratio, to receive rituximab or azathioprine. They were stratified at randomisation according to:

1. ANCA type: PR3-ANCA or MPO-ANCA.
2. Relapse type: severe or non-severe. A severe relapse was defined as the development of a new or recurrent item of major disease activity on BVAS/WG. A non-severe relapse was any increase in disease activity that did not meet the definition of a severe relapse.

3. Oral glucocorticoid induction regimen: high or low dose.

Maintenance phase interventions

Rituximab
Intravenous rituximab 1000 mg repeated every 4 months for five doses (months 4, 8, 12, 16 and 20 from enrolment). This dose was based on prior observational studies and the interval was designed to minimise the risk of relapse. Rituximab was withheld for plasma IgG <3 g/L and could be recommenced at the next treatment time point if plasma IgG >3 g/L.

Azathioprine
Oral azathioprine 2 mg/kg/day for 24 months, then reduced by 50% and withdrawn at month 27. Patients intolerant to azathioprine received either methotrexate (oral or subcutaneous), 25 mg/week, if their estimated glomerular filtration rate (eGFR) was >50 mL/min, or mycophenolate mofetil 2 g/day, if their eGFR was ≤50 mL/min.

Glucocorticoids
A prednisone/prednisolone dose of 10 mg/day or less was a requirement for randomisation at month 8. This dose was reduced to 5 mg/day by month 12 and 2.5 mg/day and withdrawn at month 16 (online supplemental eTable 1). Patients experiencing a first minor relapse received an increase in oral prednisone/prednisolone to 20 mg/day reducing over 6 weeks to their dose prior to the relapse and continued their other immunosuppressive agent (rituximab or azathioprine). After a second minor or first major relapse treatment was according to physician discretion.

Other treatments
Medications to prevent *pneumocystis (carinii) jiroveci* infection and/or to prevent osteoporosis were prescribed according to local practice.

Assessments
Evaluations, including clinical, laboratory and patient-reported outcomes, were performed at months 4, 8, 12, 16, 20, 24, 27, 30, 36, 42 and 48. The common closeout date for those patients remaining in the trial was when the final patient reached month 36.

Outcomes
The primary outcome was time from randomisation to disease relapse, defined as the return or first appearance of at least one item on BVAS/WG. Major relapse required at least one major BVAS/WG item. Relapses were reviewed by a blinded adjudication committee. Secondary outcomes included the proportions who maintained remission at the end of the maintenance phase, or end of the follow-up phase; time to major relapse;
cumulative accrual of damage measured by the Combined Disease Assessment instrument17 (online supplemental eTable 2); cumulative glucocorticoid exposure; health-related quality of life measures using the SF-36; rates of serious adverse events (SAEs), hypogammaglobulinaemia, defined as plasma IgG <5 g/L and infections.

Compliance
Compliance for the rituximab group was defined as receipt of five doses of rituximab (unless withheld for IgG <3 g/L) and no oral immunosuppressive agents administered. Compliance in the azathioprine group was defined as ongoing receipt of azathioprine, methotrexate or mycophenolate mofetil between months 4 and 24.

Statistical analyses
Sample size calculation
Enrolment continued until at least 160 patients were randomised. This sample size was calculated based on a goal of achieving 90% power under the alternative hypothesis of a HR of 0.42 at the 5% significance level with 58 observed relapses. This assumed a drop-out rate of 5% at 24 months and a relapse-free rate of 75% and 50% at 48 months in the rituximab and azathioprine arms, respectively.

Analysis
Results are reported for the 170 randomised patients, except for safety parameters for which data on all 188 enrolled patients are presented. The primary intention-to-treat analysis was based on a Cox proportional hazard model, adjusted for the stratification
Vasculitis

因素（ANCA类型、复发严重程度和泼尼松诱导方案）的影响不同分布的复发自由生存率间在利妥昔单抗和硫唑嘌呤组之间的差异。使用封闭测试程序。首先，零假设在所有时间点的HR为1时进行检验。如果在5%水平上被拒绝，然后将两个子假设预设为时间-相关的自变量；在24个月内和之后24个月。

危害比和95% CI被报告。P值小于5%被认为是统计学显著。

Kaplan-Meier估计用于24和48个月的复发自由生存和对应95% CI的比较。数据分析使用R V.3.6.1。

结果

患者特征

188名患者被纳入并接受了利妥昔单抗和糖皮质激素的诱导治疗。170（90%）在4个月时随机分配到利妥昔单抗（N=85）或硫唑嘌呤（N=85）治疗组，并成为当前分析的患者群体（图1和表1）。123（72%）有PR3-ANCA，47（38%）有MPO-ANCA。106（62%）患者至少有一个主要疾病活动项目，48（28%）接受了高剂量糖皮质激素诱导方案。图1显示了入组患者的分布。

结果

在结合的维持和随访阶段，利妥昔单抗优于硫唑嘌呤防止重大或轻微疾病复发：HR 0.41，95% CI 0.27到0.61，p<0.001（图2）。在维持阶段HR为0.35，95% CI 0.18到0.66，p=0.001，而在随访阶段HR为0.45，95% CI 0.26到0.78，p=0.004。

图2 显示了利妥昔单抗和硫唑嘌呤的复发自由生存概率。黑色箭头代表1000mg剂量的利妥昔单抗。虚线垂直线表示按照协议末维护治疗期和开始随访期。阴影区域表示95% CI。

图2 显示了利妥昔单抗和硫唑嘌呤的复发自由生存概率。黑色箭头代表1000mg剂量的利妥昔单抗。虚线垂直线表示按照协议末维护治疗期和开始随访期。阴影区域表示95% CI。

图2 显示了利妥昔单抗和硫唑嘌呤的复发自由生存概率。黑色箭头代表1000mg剂量的利妥昔单抗。虚线垂直线表示按照协议末维护治疗期和开始随访期。阴影区域表示95% CI。
relapse-free survival rate was 0.85, 95%CI 0.78 to 0.93, for the rituximab compared with 0.61, 95%CI 0.51 to 0.73, for the azathioprine groups. During the follow-up phase, there were 33 relapses in 25 from the rituximab compared with 49 relapses in 28 in the azathioprine groups. Five patients in the rituximab group experienced a major relapse during the follow-up period compared with 11 in the azathioprine group. At month 48, the rate for continued remission was 0.50, 95% CI 0.30 to 0.70, compared with 11 in the azathioprine group. At month 24, by which time the protocol-defined immunosuppressive therapy were 0×10⁹/L (0–3) in the rituximab group and 0×10⁹/L (0–5) in the azathioprine group. The median percentage of CD19 cells remained zero (0–5) in the rituximab group but increased to 37.25 (range 2.8–61.6) and 36.5 (1.5–58.1) and median mental component scores at randomisation were 54.55 (19.6–67.7) and 53.8 (16.7–72.6). Scores remained stable across the trial, both during the maintenance and follow-up phases (online supplemental eFigure 2).

### Compliance with treatment per protocol

81/85 (95%) patients in the rituximab group were compliant and 78/85 (92%) in the azathioprine group. During the follow-up phase, 10/85 (12%) patients in the rituximab and 15/85 (18%) patient in the azathioprine groups continued immunosuppression. When the 11 patients non-compliant during the treatment period with the protocol-defined immunosuppressive therapy were excluded in the analysis, the HR for relapse was 0.38, 95%CI 0.25 to 0.58, p<0.001. When the 25 patients non-complaint during either the treatment or the follow-up phase were excluded in the analysis, the HR for relapse was 0.36, 95%CI 0.23 to 0.57, p<0.001.

The median cumulative prednisolone dose during the maintenance phase was identical in both groups (median 2100 mg, ranges 0–5700 mg in rituximab and 0–9000 mg in the azathioprine groups), deviations from the protocol were common, 44 (52%) in the rituximab and 57 (67%) in the azathioprine groups reported at least one deviation during the trial. At month 24, by which time the protocol-required cessation of glucocorticoids, 22/77 (29%) in the rituximab and 35/76 (46%) in the azathioprine groups were still receiving glucocorticoids, mean daily doses=2.28 mg (SD=5.45) for the rituximab and 2.8 mg (SD 5.5) for the azathioprine groups.

### Damage assessment

There was no difference in the accrual of damage between groups. The modified Combined Damage Assessment score increased by a mean of 0.571 (SD 0.909) and 1.09 (SD 1.18) in the rituximab group compared with 0.533 (SD 0.777) and 1.38 (SD 1.65) in the azathioprine group during the maintenance phase and whole trial, respectively.

### Quality of life measures

No differences were observed between study groups in any domains of the SF-36 score. In the rituximab and azathioprine groups, median physical component scores at randomisation were reduced at 37.25 (range 2.8–61.6) and 36.5 (1.5–58.1) and median mental component scores were 54.55 (19.6–67.7) and 53.8 (16.7–72.6). Scores remained stable across the trial, both during the maintenance and follow-up phases (online supplemental eFigure 2).

### CD19-positive B cells

During the maintenance phase, the median CD19 cell counts were 0×10⁹/L (0–3) in the rituximab group and 0×10⁹/L (0–5) in the azathioprine group. The median percentage of CD19 cells remained zero (0–5) in the rituximab group but increased to 0.1% (0–29) at month 12 and 0.3% (0–35.1) at month 24 in the azathioprine group. During the follow-up phase, the median CD19 cell counts were lower in the azathioprine group, this was confounded by the use of rituximab to treat relapses in this group (online supplemental eFigure 3).

### Safety

Sixty-nine SAEs occurred in 37 (44%) patients in the rituximab and 105 in 48 (56%) in the azathioprine groups (table 2). There was no difference in time to first SAE between groups (online supplemental eFigure 4). Nineteen (22%) patients in the rituximab and 31 (36%) patients in the azathioprine groups experienced at least one SAE during the treatment period.

---

**Figure 3**  Multivariate model of clinical predictors for relapse in the RITAZAREM trial. Induction regimen refers to glucocorticoid dose. 1A—1 mg/kg/day starting dose (maximum 60 mg daily); 1B—0.5 mg/kg/day starting dose (maximum 30 mg daily). PR3, proteinase 3; MPO, myeloperoxidase. The estimates are from a multiple regression model that simultaneously adjusts for the treatment and all covariates.
severe infections occurred in 15 (18%) patients in the rituximab and 27 in 19 (22%) patients in the azathioprine groups (online supplemental eTable 3). One-hundred and ninety-seven and 207 non-severe infections occurred in 54 (64%) and 62 (73%) patients in the rituximab and azathioprine groups, respectively. One case of progressive multifocal leukoencephalopathy occurred after the induction period in a patient not randomised into the maintenance phase of the trial. Thirty-six (42%) patients in the rituximab group had a plasma IgG level <5 g/L at some point during the trial and 8 (9%) had a plasma IgG level <3 g/L compared with 26 (31%) and 6 (7%) patients in the azathioprine group. A lower plasma IgG level at baseline (OR 0.52 baseline IgG; 95% CI 0.40 to 0.65, p<0.001) and high-dose glucocorticoids during induction (OR 8.6; 95% CI 3.02 to 27.58, p<0.001) were associated with the development of hypogammaglobulinaemia (table 3). One patient, from the rituximab group, received intravenous immunoglobulin during the trial for treatment of hypogammaglobulinaemia and repeated infections. Eleven patients developed a new malignancy during the trial: five in the rituximab (skin (2), prostate (1), pancreas (1), oesophagus (1)) and six in the azathioprine groups (skin (5), pancreas (1)). Four patients died during the trial; three in the rituximab (infection (1), malignancy (1), other (1)) and one in the azathioprine groups (malignancy).

**DISCUSSION**

This international, randomised, controlled trial demonstrated that rituximab was superior to azathioprine for prevention of disease relapse in patients with AAV with a prior history of relapse, following reinduction of remission with rituximab and glucocorticoids, and there was lower average glucocorticoid exposure in the rituximab group.

The MAINRITSAN 1 trial demonstrated the superiority of rituximab over azathioprine for the prevention of relapse following induction of remission with cyclophosphamide in a study population with predominantly newly diagnosed AAV patients. The higher relapse rate found in this trial compared with the MAINRITSAN 1 trial reflects differences in patient populations and trial design. RITAZAREM recruited patients at relapse, which is associated with a higher subsequent relapse risk. Both major and minor relapses were reported as part of the primary endpoint of relapse-free survival in RITAZAREM, reflecting the importance of minor relapses in cumulative treatment exposure, and the follow-up period was longer, at 48 months. The cumulative rituximab dose during the maintenance phase, 5000 mg, was double that used in MAINRITSAN, yet relapses were still seen in 15% of the rituximab group during treatment, identifying a subset of patients with disease refractory to higher dose rituximab. The lower relapse risk in those with major BVAS/WG items at enrolment is consistent with previous observations of lower relapse risk with worse renal vasculitis. Furthermore, after discontinuation of therapy, relapses were frequent in both groups indicating that the benefit of rituximab, even at a high dose, was not sustained beyond the treatment period.

SAEs and infections were common, consistent with previous studies in AAV, and there were no new safety signals for these medications in this population. Hypogammaglobulinaemia, secondary immunodeficiency and impaired vaccine responses, is a concern with use of repeated doses of rituximab. Although median plasma IgG levels were stable in both the rituximab and azathioprine groups across the trial, 42% of patients in the rituximab group and 31% in the azathioprine group developed a plasma IgG level <5 g/L; however, it should be noted that all patients had received rituximab induction at trial entry. In RITAZAREM, higher glucocorticoid exposure and lower baseline plasma IgG levels were associated with the development of hypogammaglobulinaemia, a finding consistent with a prior report. In the context of the COVID-19 pandemic, poorer vaccine responses, both in term of absolute antibody titres and neutralising capacity, when compared with non-B cell depleting immunosuppressive agents, have been observed in several cohorts despite booster vaccine doses and are important consideration when making therapeutic decisions.

The strengths of this study include this being the largest cohort of patients with relapsing AAV recruited into a clinical trial, centralised randomisation and recruitment from 29 centres across four continents, minimising centre or regional bias. The study had low rates of treatment crossover and a long period of follow-up after trial medications were discontinued, a design aimed at detecting the prolonged effects or safety issues of the interventions.

The study was limited by use of open-label trial medication, but potential impact on trial end-points was counterbalanced by a blinded adjudication end-point committee. Extended use

**Table 2 Adverse events according to treatment regimen in the RITAZAREM trial**

<table>
<thead>
<tr>
<th>Number (% of patients with a serious adverse event</th>
<th>Total (N=188)</th>
<th>Rituximab (N=85)</th>
<th>Azathioprine (N=85)</th>
<th>Not randomised (N=18)</th>
</tr>
</thead>
<tbody>
<tr>
<td>92 (49%)</td>
<td>37 (44%)</td>
<td>48 (56%)</td>
<td>7 (39%)</td>
<td></td>
</tr>
<tr>
<td>39 (21%)</td>
<td>15 (18%)</td>
<td>19 (22%)</td>
<td>5 (28%)</td>
<td></td>
</tr>
<tr>
<td>119 (63%)</td>
<td>54 (64%)</td>
<td>62 (73%)</td>
<td>3 (17%)</td>
<td></td>
</tr>
<tr>
<td>66 (35%)</td>
<td>36 (42%)</td>
<td>26 (31%)</td>
<td>4 (22%)</td>
<td></td>
</tr>
<tr>
<td>17 (9%)</td>
<td>8 (9%)</td>
<td>6 (7%)</td>
<td>3 (17%)</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3 Multivariable model of predictors for the development of hypogammaglobulinaemia in the RITAZAREM trial**

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR</th>
<th>95% CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintenance treatment (rituximab vs azathioprine)</td>
<td>2.2</td>
<td>(0.87 to 5.72)</td>
<td>0.104</td>
</tr>
<tr>
<td>Glucocorticoid induction regimen (TA vs 1B)</td>
<td>8.6</td>
<td>(0.02 to 27.58)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ANCA status at enrolment (anti-PR3 vs anti-PMPO)</td>
<td>0.78</td>
<td>(0.27 to 2.26)</td>
<td>0.639</td>
</tr>
<tr>
<td>Type of relapse (severe vs non-severe)</td>
<td>2.2</td>
<td>(0.82 to 6.07)</td>
<td>0.124</td>
</tr>
<tr>
<td>Previous rituximab (yes vs no)</td>
<td>1.2</td>
<td>(0.41 to 3.53)</td>
<td>0.740</td>
</tr>
<tr>
<td>Previous cyclophosphamide (yes vs no)</td>
<td>1.1</td>
<td>(0.20 to 6.36)</td>
<td>0.944</td>
</tr>
<tr>
<td>Previous rituximab or cyclophosphamide (yes vs no)</td>
<td>0.73</td>
<td>(0.57 to 128.37)</td>
<td>0.144</td>
</tr>
<tr>
<td>Baseline plasma IgG (g/L)</td>
<td>0.52</td>
<td>(0.40 to 0.65)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Intercept</td>
<td>0.013</td>
<td>(0.00 to 0.12)</td>
<td></td>
</tr>
</tbody>
</table>

Glucocorticoid induction regimen: 1A=1 mg/kg/day starting dose; 1B=0.5 mg/kg/day starting dose.
*Baseline plasma IgG level was centred around the mean value (9.56). The intercept gives an estimate of the absolute odds for a patient with the mean value of baseline IgG, and the reference levels of the other binary predictors.

MPD, myeloperoxidase; PR3, proteinase 3.
of glucocorticoids was employed due to their known impact on relapse risk and the inclusion of a population at high risk of relapse, but their value could not be assessed and there remains a need to minimise glucocorticoids among patients with relapsing disease who have already accrued considerable exposure to glucocorticoids.27 Prior immunosuppressive exposure may have potentially confounded the results, but exposures were comparable across the treatment groups.

In conclusion, the results of the RITAZAREM trial show that repeat-dose rituximab is more effective than azathioprine for prevention of relapse for patients with AAV with relapsing disease induced with rituximab and glucocorticoids. These data extend previous reports on the efficacy of rituximab for induction of remission for relapsing disease and confirms the place of rituximab as the standard of care for maintenance therapy. The results should also prompt further reductions in glucocorticoid exposure for AAV.28 Despite a higher dose rituximab regimen than previously studied, relapses still occurred, and this, together with the increased risk of relapse after stopping rituximab, and the associated safety risks, illustrate the need for newer therapeutic agents for AAV. No new safety signals were seen with rituximab, and infections and hypogammaglobulinaemia remaining common problems in this patient population. Future treatment strategies for AAV may necessitate a more individualised approach, taking into account the risk of relapse balanced against the risk of adverse events with extended treatment.29

Author affiliations
1. Medicine, University of Cambridge, Cambridge, UK
2. Renal Medicine, Addenbrooke’s Hospital, Cambridge, UK
3. Pulmonary Medicine, Mayo Clinic, Rochester, Minnesota, USA
4. Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
5. Nephrology, University Hospitals of Leicester NHS Trust, Leicester, UK
6. NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK
7. Nephrology, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden
8. Nephrology, Ipswich Hospital NHS Trust, Ipswich, UK
9. Rheumatology, University of Toronto, Toronto, Ontario, Canada
10. Rheumatology, University of Leicester, Leicester, UK
11. Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
12. Nephrology, East Kent Hospitals University NHS Foundation Trust, Canterbury, UK
13. Rheumatology, Nottingham University Hospitals NHS Trust, Nottingham, UK
14. Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA
15. Hemovascular Medicine and Artificial Organs, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
16. Allergy and Clinical Immunology, Chiba University, Chiba, Japan
17. Rheumatology, University of Michigan, Ann Arbor, Michigan, USA
18. Nephrology, University of Birmingham, Birmingham, UK
19. The Clinical and Translational Research Center, Kyoto Prefectural University of Medicine, Kyoto, Japan
20. Medicine, McMaster University, Hamilton, Ontario, Canada
21. Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, UK
22. Rheumatology, The University of Utah, Salt Lake City, Utah, USA
23. First Department of Internal Medicine, Kyoto University School of Medicine, Tokyo, Japan
24. Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, Ohio, USA
25. Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
26. Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
27. Vasculitis and Lupus clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
28. UNC Kidney Center, Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
29. Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
30. Nephrology, Royal Adelaide Hospital, Adelaide, South Australia, Australia

Acknowledgements

The RITAZAREM trial is directed by the European Vasculitis Society and the Vasculitis Clinical Research Consortium (VCRC). The primary sponsor is Cambridge University Hospitals NHS Foundation Trust, and there are collaboration and data-sharing agreements with the University of Pennsylvania and the University of Miyazaki and Okayama University in Japan.

Collaborators

RITAZAREM co-investigators were: Dr Y Arimura (Kyorin University, Japan); Dr M Clarkson (Cork University Hospital, Ireland); Dr J de Zoya (North Shore Hospital, Auckland, New Zealand); Dr T Endo (Kitano Hospital, Japan); Dr Y Hamano (Tokyo Metropolitan Geriatric Hospital, Japan); Dr H Kono (Teikyo University Hospital, Tokyo, Japan); Dr S Lawman (Brighton Royal Sussex County Hospital, UK); Dr E Muso (Kitano Hospital, Japan); Dr Rula Hajj-Ali (Cleveland Clinic, Cleveland, Ohio, USA); Dr K Sada (Okayama University, Japan); Dr R Smith (Ipswich Hospital, UK); Dr K Suzuki (Teikyo University, Japan); Dr T Tsukamoto (Kitano Hospital, Japan); Dr S Uchida (Tokyo University Hospital, Tokyo, Japan); Dr A Vaglio (University of Parma, Italy); and Dr R Watts (Ipswich Hospital, UK).

Contributors

RMS, DJ and PAM conceived and designed the study. US, RJB and SB were also involved in study design. RMS, SB, MN, DJ and PAM analysed the data and interpreted the results. RMS wrote the manuscript with support from DJ and PAM. All contributors collected data and contributed critical appraisal to the final manuscript. RMS is guarantor for the manuscript.

Funding

The RITAZAREM trial was supported by grant number 18706 from Arthritis Research UK (now Versus Arthritis) and by Roche/Genentech (MA28150). Roche/Genentech also provided rituximab for the study. The Vasculitis Clinical Research Consortium (VCRC) is part of the United States National Institutes of Health Rare Diseases Clinical Research Network, an initiative of the National Center for Advancing Translational Science (NCATS). The VCRC has received funding from NCATS, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (USA AR057319), the National Center for Research Resources (USA RR019497). The Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan. RS and DJ were also supported by the National Institute for Health Research, Cambridge Biomedical Research Centre and the Cambridge Clinical Trials Unit.

Competing interests

RMS reports research grant for the trial from Roche during the conduct of the study. RB reports contract with Roche for provision of rituximab for another trial. US reports grants from Genentech, during the conduct of the study. AB has received consulting fees from AstraZeneca, Bayer, ChemoCentryx, Fresenius, and Vifor and honoraria for lectures from AstraZeneca, Bayer, ChemoCentryx, Fresenius, and Vifor. AB sits on the Advisory Board for AstraZeneca and Bayer and is Chair of the Immunopharmacology working group of ERA. BC has received honoraria from AstraZeneca and NAPP Pharmaceuticals. SC is on an advisory board for Sanofi. CK reports participation in an advisory board for CSL Vifor, FD reports grants from NIDDK/NIH, NIAID/NIH and NHLBI/NIH; royalties from UpToDate; consulting fees from Novartis and Forma Therapeutics; participation on advisory boards for Merck, Forma Therapeutics and Bayer. LF reports grants from Bristol-Meyer Squibb and Novartis and consulting fees from Chemocentryx. SFU reports grants and honoraria from Chugai Pharmaceutical Co., Ltd. PSF reports a grant from the frühreife Krebsgesellschaft Berlin, Germany; grants from the National Institute for Health Research, UK; grants from the European Research Council, ERC, and the Deutsche Krebshilfe, Germany; grants from the German Research Foundation, DFG, and the German Ministry for Education and Research, BMBF, Germany; grants from the National Cancer Institute, Bethesda, USA; grants from the National Institutes of Health, USA; grants from the German Cancer Aid and the German Cancer Society, Germany; and grants from the German Cancer Research Center. SL reports grants from Bristol-Meyer Squibb, Roche/Genentech also provided rituximab for the study. The Vasculitis Clinical Research Consortium (VCRC) is part of the United States National Institutes of Health Rare Diseases Clinical Research Network, an initiative of the National Center for Advancing Translational Science (NCATS). The VCRC has received funding from NCATS, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (USA AR057319), the National Center for Research Resources (USA RR019497). The Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan. RS and DJ were also supported by the National Institute for Health Research, Cambridge Biomedical Research Centre and the Cambridge Clinical Trials Unit.

Competing interests

RMS reports research grant for the trial from Roche during the conduct of the study. RB reports contract with Roche for provision of rituximab for another trial. US reports grants from Genentech, during the conduct of the study. AB has received consulting fees from AstraZeneca, Bayer, ChemoCentryx, Fresenius, and Vifor and honoraria for lectures from AstraZeneca, Bayer, ChemoCentryx, Fresenius, and Vifor. AB sits on the Advisory Board for AstraZeneca and Bayer and is Chair of the Immunopharmacology working group of ERA. BC has received honoraria from AstraZeneca and NAPP Pharmaceuticals. SC is on an advisory board for Sanofi. CK reports participation in an advisory board for CSL Vifor, FD reports grants from NIDDK/NIH, NIAID/NIH and NHLBI/NIH; royalties from UpToDate; consulting fees from Novartis and Forma Therapeutics; participation on advisory boards for Merck, Forma Therapeutics and Bayer. LF reports grants from Bristol-Meyer Squibb and Novartis and consulting fees from Chemocentryx. SFU reports grants and honoraria from Chugai Pharmaceutical Co., Ltd. PSF reports a grant from the frühreife Krebsgesellschaft Berlin, Germany; grants from the National Institute for Health Research, UK; grants from the European Research Council, ERC, and the Deutsche Krebshilfe, Germany; grants from the German Research Foundation, DFG, and the German Ministry for Education and Research, BMBF, Germany; grants from the National Cancer Institute, Bethesda, USA; grants from the National Institutes of Health, USA; grants from the German Cancer Aid and the German Cancer Society, Germany; and grants from the German Cancer Research Center. SL reports grants from Bristol-Meyer Squibb, Roche/Genentech also provided rituximab for the study. The Vasculitis Clinical Research Consortium (VCRC) is part of the United States National Institutes of Health Rare Diseases Clinical Research Network, an initiative of the National Center for Advancing Translational Science (NCATS). The VCRC has received funding from NCATS, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (USA AR057319), the National Center for Research Resources (USA RR019497). The Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan. RS and DJ were also supported by the National Institute for Health Research, Cambridge Biomedical Research Centre and the Cambridge Clinical Trials Unit.
References